<DOC>
	<DOCNO>NCT01998061</DOCNO>
	<brief_summary>There report suggest continuous administration epidermal growth factor receptor-tyrosine kinase inhibitor ( EGFR-TKIs ) advantageous patient gradual disease progression observe establishment clinical benefit EGFR-TKIs . However , whether EGFR TKI without chemotherapy provide survival benefit formally evaluate .</brief_summary>
	<brief_title>Continuation TKI With Without Chemotherapy Beyond Gradual Progression</brief_title>
	<detailed_description>We design clinical trial compare efficacy continuation EGFR TKI without chemotherapy patient beyond gradual progression .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : Patient confirm stage IV NSCLC pathologic histology cytology . Males female age ≥18 year , &lt; 75 year . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Life expectancy ≥12 week . Males female contraceptive period trial 8 week last administration drug . Definition gradual progression : 1 . Slow PD ( 6 month partial response/stable disease ) , 2 . Asymptomatic minimal PD , 3 . New brain metastasis control locally . Patients asymptomatic , treat brain metastasis eligible trial participation . Adequate bone marrow , renal , liver function require . Able comply require protocol followup procedure , able receive oral medication . Institutional review boardapproved informed consent obtain every patient initiation trialspecific procedure treatment . Exclusion criteria： Any unstable systemic disease ( include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within previous year , serious cardiac arrhythmia require medication , hepatic , renal , metabolic disease ) . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability take oral medication , active peptic ulcer disease . Female subject pregnant breastfeeding . Adequate hematological function : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L , Platelet count ≥100 x 109/L . Adequate renal function : Serum creatinine ≤ 1.5 x ULN , ≥ 50 ml/min . Adequate liver function : Total bilirubin £ 1.5 x upper limit normal ( ULN ) Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) &lt; 2.5 x ULN absence liver metastasis , &lt; 5 x ULN case liver metastasis . Patient assess investigator unable unwilling comply requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>